PMID- 27110370
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160425
LR  - 20231111
IS  - 2052-4897 (Print)
IS  - 2052-4897 (Electronic)
IS  - 2052-4897 (Linking)
VI  - 4
IP  - 1
DP  - 2016
TI  - Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 
      diabetes inadequately controlled via diet and/or a single oral antihyperglycemic 
      agent: a multicenter, randomized trial.
PG  - e000190
LID - 10.1136/bmjdrc-2015-000190 [doi]
LID - e000190
AB  - PURPOSE: A step-up strategy for diet therapy and/or single oral antihyperglycemic 
      agent (OHA) regimens has not yet been established. The aim of this study was to 
      evaluate hemoglobin A1c (HbA1c) as a primary end point, and the pleiotropic 
      effects on metabolic and cardiovascular parameters as secondary end points, of 
      sitagliptin versus voglibose in patients with type 2 diabetes with inadequate 
      glycemic control while on diet therapy and/or treatment with a single OHA. 
      METHODS: In this multicenter, randomized, open-label, parallel-group trial, a 
      total of 260 patients with inadequately controlled type 2 diabetes (HbA1c levels 
      >6.9%) were randomly assigned to receive either sitagliptin (50 mg, once daily) 
      or voglibose (0.6 mg, thrice daily) for 12 weeks. The primary end point was HbA1c 
      levels. RESULTS: Patients receiving sitagliptin showed a significantly greater 
      decrease in HbA1c levels (-0.78+/-0.69%) compared with those receiving voglibose 
      (-0.30+/-0.78%). Sitagliptin treatment also lowered serum alkaline phosphatase 
      levels and increased serum creatinine, uric acid, cystatin-C and homeostasis 
      model assessment-beta values. Voglibose increased low-density 
      lipoprotein-cholesterol levels and altered serum levels of several fatty acids, 
      and increased Delta-5 desaturase activity. Both drugs increased serum adiponectin. 
      The incidence of adverse events (AEs) was significantly lower in the sitagliptin 
      group, due to the decreased incidence of gastrointestinal AEs. CONCLUSIONS: 
      Sitagliptin shows superior antihyperglycemic effects compared with voglibose as a 
      first-line or second-line therapy. However, both agents possess unique 
      pleiotropic effects that lead to reduced cardiovascular risk in Japanese people 
      with type 2 diabetes. TRIAL REGISTRATION NUMBER: UMIN 000003503.
FAU - Matsushima, Yukiko
AU  - Matsushima Y
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; Department of Disease Control and 
      Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 
      Ishikawa, Japan; ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa, Japan.
FAU - Takeshita, Yumie
AU  - Takeshita Y
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; Department of Disease Control and 
      Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 
      Ishikawa, Japan; ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa, Japan.
FAU - Kita, Yuki
AU  - Kita Y
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; ERA-DM Chapter 1 Study Group, 
      Kanazawa, Ishikawa, Japan.
FAU - Otoda, Toshiki
AU  - Otoda T
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; ERA-DM Chapter 1 Study Group, 
      Kanazawa, Ishikawa, Japan.
FAU - Kato, Ken-Ichiro
AU  - Kato K
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; ERA-DM Chapter 1 Study Group, 
      Kanazawa, Ishikawa, Japan.
FAU - Toyama-Wakakuri, Hitomi
AU  - Toyama-Wakakuri H
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; ERA-DM Chapter 1 Study Group, 
      Kanazawa, Ishikawa, Japan.
FAU - Akahori, Hiroshi
AU  - Akahori H
AD  - ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa , Japan.
FAU - Shimizu, Akiko
AU  - Shimizu A
AD  - ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa , Japan.
FAU - Hamaguchi, Erika
AU  - Hamaguchi E
AD  - ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa , Japan.
FAU - Nishimura, Yasuyuki
AU  - Nishimura Y
AD  - ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa , Japan.
FAU - Kanamori, Takehiro
AU  - Kanamori T
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; ERA-DM Chapter 1 Study Group, 
      Kanazawa, Ishikawa, Japan.
FAU - Kaneko, Shuichi
AU  - Kaneko S
AD  - Department of Disease Control and Homeostasis , Kanazawa University Graduate 
      School of Medical Sciences , Kanazawa, Ishikawa , Japan.
FAU - Takamura, Toshinari
AU  - Takamura T
AD  - Department of Endocrinology and Metabolism, Kanazawa University Graduate School 
      of Medical Sciences, Kanazawa, Ishikawa, Japan; Department of Disease Control and 
      Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, 
      Ishikawa, Japan; ERA-DM Chapter 1 Study Group, Kanazawa, Ishikawa, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160419
PL  - England
TA  - BMJ Open Diabetes Res Care
JT  - BMJ open diabetes research & care
JID - 101641391
PMC - PMC4838664
OTO - NOTNLM
OT  - A1C
OT  - Drug Therapy
OT  - Fatty Acid Desaturase(s)
EDAT- 2016/04/26 06:00
MHDA- 2016/04/26 06:01
PMCR- 2016/04/19
CRDT- 2016/04/26 06:00
PHST- 2015/12/24 00:00 [received]
PHST- 2016/02/04 00:00 [revised]
PHST- 2016/02/15 00:00 [accepted]
PHST- 2016/04/26 06:00 [entrez]
PHST- 2016/04/26 06:00 [pubmed]
PHST- 2016/04/26 06:01 [medline]
PHST- 2016/04/19 00:00 [pmc-release]
AID - bmjdrc-2015-000190 [pii]
AID - 10.1136/bmjdrc-2015-000190 [doi]
PST - epublish
SO  - BMJ Open Diabetes Res Care. 2016 Apr 19;4(1):e000190. doi: 
      10.1136/bmjdrc-2015-000190. eCollection 2016.